-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $276

Benzinga·03/24/2026 15:14:19
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $270 to $276.